Five Biomarkers You Should Know About

Contents
What are biomarkers?
Biomarkers are measurable substances or features in the body that give information about health, including signs of a normal process, an abnormal process, or a disease. Various molecules such as DNA (genes), proteins, or hormones can be biomarkers.
In cancer care, biomarkers are often called tumor markers. The NCI explains that a tumor marker can be made by cancer cells or by other cells of the body in response to cancer or to certain noncancerous conditions. They can be located in the blood, stool, urine, tumor tissues, or other bodily fluids.
Biomarkers can include:
- Proteins
- Gene mutations
- Extra copies of genes
- Missing genes, and;
- Other molecules.
What are biomarkers used for?
Biomarkers are helpful in diagnosis, prognosis estimation, cancer stage determination, identification of residual or recurrent cancer post-treatment, evaluation of treatment efficacy, and monitoring for treatment cessation.
For instance, biomarker test kits such as the DiviTum TKa blood test measure thymidine kinase activity, an enzyme linked to cell growth. In the US, the FDA cleared this test as an aid in monitoring disease progression in postmenopausal women already diagnosed with hormone receptor-positive metastatic breast cancer; it is not meant for cancer screening or diagnosis.
A high level of a circulating tumor marker may suggest the possibility of cancer. It is not, however, enough to diagnose cancer on its own. Elevations of particular tumor markers might also result from non-cancer-related conditions.
Moreover, not every patient with a specific form of cancer has high levels of the corresponding tumor marker. For a thorough cancer diagnosis, therefore, the evaluation of circulating tumor markers is usually combined with the findings of other tests, like biopsies or imaging.
Five biomarkers you should know about
There are numerous types of biomarkers. Here are five major ones you should know about.
1. Breast cancer 1 (BRCA1) & breast cancer 2 (BRCA2) gene mutations
BRCA1 and BRCA2 are the genes linked with hereditary breast and ovarian cancer. These genes usually serve as defenses against specific types of cancer. However, certain mutations in BRCA1 and BRCA2 can interfere with their normal function, raising the risk of inherited breast, ovarian, and other cancers.
The possibility of carrying a BRCA1 or BRCA2 mutation is increased in families with a high incidence of breast or ovarian cancer. Family members with BRCA1 or BRCA2 mutations usually have the same genetic altered state since these abnormalities are inherited.
The process of testing for these biomarkers is known as genetic testing. Your physician may recommend testing with a multigene panel, which simultaneously searches for abnormalities in multiple genes, including BRCA1 and BRCA2.
A positive test means you carry a harmful change in one of these genes and have a higher risk of certain cancers. It cannot tell whether or when cancer will develop, and some carriers never get cancer. A doctor or genetic counselor can explain options such as earlier or more frequent screening.
A negative test can mean different things depending on your personal and family history, according to the NCI’s BRCA fact sheet. It does not mean you will not get cancer. You still have the same cancer risks as the general population, where about 13% of women develop breast cancer in their lifetime, and family history may still raise your risk.
2. Alpha-fetoprotein (AFP)
In cases of chronic liver disorders, such as hepatitis and cirrhosis, AFP levels may steadily rise.
Because certain tumors are linked to noticeably higher AFP concentrations, the AFP test is helpful as a tumor marker. Both hepatoblastoma, a rare liver cancer that mainly affects infants and young children, and hepatocellular carcinoma, the most frequent type of liver cancer, are associated with elevated AFP levels.
Additionally, increased AFP levels are found in some ovarian or testicular germ cell tumors. AFP is also normally high during pregnancy.
3. Prostate-specific antigen (PSA)
Prostate cancer is one of the most common cancers in men. More screening has led to more cases being found.
Prostate-specific antigen, or PSA, is a protein made by both normal and cancerous prostate cells. Prostate cancer and benign conditions, especially an enlarged prostate (BPH) and prostatitis, can all raise PSA levels in the blood.
PSA screening is not recommended for all men. For men aged 55 to 69, the NCI’s PSA fact sheet cites US Preventive Services Task Force advice that screening should be an individual decision made after discussing benefits and harms with a clinician.
4. Carcinoembryonic antigen (CEA)
As a non-specific serum biomarker, carcinoembryonic antigen (CEA) has higher levels in various cancers, including breast, ovarian, medullary thyroid, and colorectal.
First described by Gold and Freedman in colon cancer tissue, CEA has since been found in several other tissues, including the stomach, tongue, esophagus, cervix, and prostate.
However, an increase in serum CEA may not always point to the exact location of cancer because it is associated with both malignant and nonmalignant medical problems.
5. Thymidine kinase (TK1)
Thymidine kinase 1 (TK1) is essential in the synthesis of DNA precursors. High TK1 levels are a marker of active cell division. TK1 has been examined as a prognostic and diagnostic agent in cancer patients’ serum.
TK1 is raised in various solid tumors and blood cancers, often in line with the stage of the disease.
For instance, in addition to several other cancer types, TK1 has been identified as a serum biomarker for breast, lung, colon, stomach, malignant melanoma, non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, and acute myeloid leukemia. Most of these uses are still being studied, and TK1 tests are not used to screen healthy people.
Conclusion
Biomarkers contribute significantly to the advancement of medicine in cancer care.
The ongoing research and development of new biomarkers continue to enhance accurate understanding of cancer biology and improve the precision of diagnostic and therapeutic approaches.
No biomarker test can diagnose cancer by itself. If you think you might need testing, for example because of a strong family history, talk with your healthcare provider about which tests make sense for you.
Sources
- Tumor Markers, National Cancer Institute
- BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet, National Cancer Institute
- Prostate-Specific Antigen (PSA) Test, National Cancer Institute
- 510(k) Substantial Equivalence Determination: DiviTum TKa (K202852), FDA


